Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is on recovery track with 52.56% gain from a 1-year low price of $41.63. The company lost -3.66% to attain the price of $63.51 on 3/14/2019. Throughout the recent session, the prices were hovering between $63.35 and $65.82. These shares are 36.29% off its target price of $86.56 and the current market capitalization stands at $3.78B. The recent change has given its price a 12.48% lead over SMA 50 and -36.38% deficit over its 52-week high. The stock witnessed 15.92% gains, 16.47% gains and -12.4% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AGIO’s volatility during a week at 3.34% and during a month it has been found around 4.82%.Agios Pharmaceuticals, Inc. (AGIO) Top Holders
Institutional investors currently hold around $3.79 billion or 0% in AGIO stock. Look at its top three institutional owners: Fmr Llc owns $575.27 million in Agios Pharmaceuticals, Inc., which represents roughly 15.22% of the company’s market cap and approximately 15.18% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 8,143,116 shares of the stock are valued at $536.79 million. The third largest holder is Vanguard Group Inc, which currently holds $304.68 million worth of this stock and that ownership represents nearly 8.06% of its market capitalization.Agios Pharmaceuticals, Inc. 13F Filings
At the end of December reporting period, 106 institutional holders increased their position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by some 6,125,653 shares, 96 decreased positions by 4,237,781 and 31 held positions by 47,119,145. That puts total institutional holdings at 57,482,579 shares, according to SEC filings. The stock grabbed 28 new institutional investments totaling 514,456 shares while 41 institutional investors sold out their entire positions totaling 1,101,419 shares.Agios Pharmaceuticals, Inc. (AGIO) Analyst Guide
Several analysts have released their opinion on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), with 3 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].